Checked
ImmunityBio, Inc.
Nasdaq: IBRX · Biological Products, (No Diagnostic Substances) · San Diego, CA
- Revenue
- $113.3M
- +668.3% vs. prior year
- Net income
- -$351.4M
- -310.2% net margin
- Total assets
- $501.9M
- Diluted EPS
- -$0.38
Company details
As reported to the SEC
- SEC CIK
- 1326110
- Stock
- Nasdaq: IBRX
- Legal Entity Identifier (LEI)
- 529900J9XLBR4HFL4B83
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- Headquarters
- 3530 John Hopkins Court, San Diego, CA 92121
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Large accelerated filer
- Phone
- (844) 696-5235
- Employer ID (EIN)
- 43-1979754
- Last annual report
- 02/23/2026
- Last quarterly report
- 08/04/2026
Formerly: NantKwest, Inc. (until 03/08/2021); Conkwest, Inc. (until 07/13/2015); ZelleRx Corp (until 10/09/2009)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $113.3M | $14.74M | $622K | $240K | $934K |
| Operating income | -$256M | -$344.2M | -$362.3M | -$351.3M | -$330.3M |
| Net income | -$351.4M | -$413.6M | -$583.2M | -$416.6M | -$346.8M |
| Diluted earnings per share | -$0.38 | -$0.62 | -$1.15 | -$1.04 | -$0.89 |
| Research and development | Not reported | $190.1M | $232.4M | $248.1M | $196M |
| Total assets | $501.9M | $382.9M | $504.5M | $362.4M | $468.9M |
| Total liabilities | $1B | $871.1M | $1.09B | $812.2M | $712.8M |
| Shareholders' equity | -$500.5M | -$489.1M | -$587M | -$447.3M | -$242.2M |
| Cash and cash equivalents | $88.33M | $143.4M | $265.5M | $104.6M | $181.1M |
| Cash from operations | -$304.9M | -$391.2M | -$366.8M | -$337.5M | -$274.4M |
| Capital expenditures | $3.85M | $6.89M | $30.58M | $78.16M | $33.56M |
Federal and state records filed under the name ImmunityBio, Inc.
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| ImmunityBio, Inc.San Diego, CA | 7 | 0 |
Subsidiaries
17 companies that ImmunityBio, Inc. owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| AccessBio LLC | SEC 10-K |
| Altor BioScience Manufacturing Company LLC | SEC 10-K |
| Altor BioScience, LLC | SEC 10-K |
| Etubics Corporation | SEC 10-K |
| GlobeImmune, Inc. | SEC 10-K |
| IgDraSol, Inc. | SEC 10-K |
| ImmunityBio Ireland Ltd. | SEC 10-K |
| Immunotherapy NANTibody, LLC | SEC 10-K |
| Inex Bio, Inc. | SEC 10-K |
| Infacell Therapeutics, Inc. | SEC 10-K |
| MCLR Parent LLC | SEC 10-K |
| Mariposa Clinic Co LLC | SEC 10-K |
| Mariposa Lab Co LLC | SEC 10-K |
| Mariposa Radiology Co LLC | SEC 10-K |
| NantCell, Inc. | SEC 10-K |
| Receptome, Inc. | SEC 10-K |
| VivaBioCell, S.p.A. | SEC 10-K |
Recent filings
127 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
42 insider ownership reports (Forms 3, 4, 5 and 144) were filed about ImmunityBio, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other biological products, (no diagnostic substances)
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Amgen IncAMGN | Thousand Oaks, CA | $36.75B | $7.71B |
| Gilead Sciences, Inc.GILD | Foster City, CA | $29.44B | $8.51B |
| Biogen Inc.BIIB | Cambridge, MA | $9.89B | $1.29B |
| Neurocrine Biosciences IncNBIX | San Diego, CA | $2.86B | $478.6M |
| Exelixis, Inc.EXEL | Alameda, CA | $2.32B | $782.6M |
| Qiagen N.V.QGEN | Pl Venlo, Netherlands | $2.09B | $424.9M |
| Moderna, Inc.MRNA | Cambridge, MA | $1.94B | -$2.82B |
| Halozyme Therapeutics, Inc.HALO | San Diego, CA | $1.4B | $316.9M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is ImmunityBio, Inc.'s CIK number?
- ImmunityBio, Inc.'s SEC Central Index Key (CIK) is 1326110.
- What is ImmunityBio, Inc.'s stock ticker?
- ImmunityBio, Inc. trades as Nasdaq: IBRX.
- What was ImmunityBio, Inc.'s revenue?
- ImmunityBio, Inc. reported revenue of $113.3M for the fiscal year ended Dec 31, 2025, +668.3% from the year before.
- When does ImmunityBio, Inc.'s fiscal year end?
- ImmunityBio, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is ImmunityBio, Inc. headquartered?
- ImmunityBio, Inc.'s principal executive office on file with the SEC is in San Diego, CA.
- What companies does ImmunityBio, Inc. own?
- ImmunityBio, Inc. lists 17 subsidiaries in its SEC filings and other public records, including AccessBio LLC, Altor BioScience Manufacturing Company LLC, Altor BioScience, LLC.
- Does ImmunityBio, Inc. sponsor H-1B visas?
- Department of Labor records show 7 certified H-1B filings and 0 certified PERM filings under the name ImmunityBio, Inc.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026